The Eurasian Journal of Medicine
Case Report

The Clinical Outcomes of COVID-19 in Patients with Behçet’s Disease: A Series of 7 Cases and Brief Review of the Literature


Division of Rheumatology and Immunology, Department of Physical Medicine and Rehabilitation, Sakarya University School of Medicine, Sakarya, Turkey

Eurasian J Med 2022; 54: 305-309
DOI: 10.5152/eurasianjmed.2021.21203
Read: 784 Downloads: 344 Published: 01 October 2022

Conventional debates surrounding the treatment of coronavirus disease 2019 still continue in the literature. Colchicine is one of the recommended agents in the treatment of coronavirus disease 2019, but there are also studies giving negative opinions for the said agent. Some researchers suggest that those patients using colchicine have milder clinic symptoms. Behçet’s disease is a multisystemic disease with an uncertain etiopathogenesis that is characterized by chronic inflammatory vasculitis. Autoimmunity is believed to play a key role in the pathogenesis of Behçet’s disease. Immunomodulator, corticosteroid, and immunosuppressive drugs are used in its treatment. Seven Behçet’s patients with coronavirus disease 2019 were presented in this study, and the drugs used, prognosis, accompanying diseases, hospitalization, and complications were discussed in the light of the literature.

Cite this article as: Nas K, Dilek G, Unan MK, et al. The clinical outcomes of COVID-19 in patients with behçet’s disease: A series of 7 cases and brief review of the literature. Eurasian J Med., 2022;54(3):305-309.

EISSN 1308-8742